Testing of acetaminophen in support of the international multilaboratory in vivo rat Pig-a assay validation trial.


Journal

Environmental and molecular mutagenesis
ISSN: 1098-2280
Titre abrégé: Environ Mol Mutagen
Pays: United States
ID NLM: 8800109

Informations de publication

Date de publication:
06 2020
Historique:
received: 10 10 2019
revised: 09 03 2020
accepted: 13 03 2020
pubmed: 19 3 2020
medline: 18 12 2020
entrez: 19 3 2020
Statut: ppublish

Résumé

Acetaminophen, a nonmutagenic compound as previously concluded from bacteria, in vitro mammalian cell, and in vivo transgenic rat assays, presented a good profile as a nonmutagenic reference compound for use in the international multilaboratory Pig-a assay validation. Acetaminophen was administered at 250, 500, 1,000, and 2,000 mg·kg

Identifiants

pubmed: 32187737
doi: 10.1002/em.22368
pmc: PMC7317746
doi:

Substances chimiques

Mutagens 0
Acetaminophen 362O9ITL9D

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

508-525

Subventions

Organisme : Janssen Pharmaceutical Companies of Johnson & Johnson
Pays : International
Organisme : Johnson & Johnson Consumer, Inc, McNeil Consumer Healthcare Division
Pays : International

Informations de copyright

© 2020 The Authors. Environmental and Molecular Mutagenesis published by Wiley Periodicals, Inc. on behalf of Environmental Mutagen Society.

Références

Environ Mol Mutagen. 2020 Jun;61(5):508-525
pubmed: 32187737
Pharm Stat. 2011 Nov-Dec;10(6):485-93
pubmed: 22127874
Mutat Res. 1997 Oct;387(2):69-88
pubmed: 9372851
Mutat Res. 1998 Jun 5;401(1-2):165-78
pubmed: 9639698
Mutat Res. 2007 Feb 3;627(1):78-91
pubmed: 17116417
Mutagenesis. 1995 Nov;10(6):467-70
pubmed: 8596464
Biol Pharm Bull. 2014;37(7):1184-90
pubmed: 24705304
Mutat Res. 1983 Dec;122(3-4):367-72
pubmed: 6656820
Toxicol Sci. 2012 Dec;130(2):328-48
pubmed: 22923490
Proc Natl Acad Sci U S A. 1989 Oct;86(20):7971-5
pubmed: 2530578
Proc Natl Acad Sci U S A. 1991 Sep 15;88(18):7958-62
pubmed: 1832771
Environ Mol Mutagen. 2007 Apr-May;48(3-4):258-69
pubmed: 16850453
Mutagenesis. 2015 May;30(3):325-34
pubmed: 25820171
Br J Pharmacol Chemother. 1966 Mar;26(3):606-14
pubmed: 5959211
Mutat Res Genet Toxicol Environ Mutagen. 2016 Nov 15;811:16-20
pubmed: 27931808
Environ Mol Mutagen. 2011 Dec;52(9):685-9
pubmed: 21976154
Mol Carcinog. 2005 Jan;42(1):9-17
pubmed: 15486947
Mutat Res. 1996 Feb 1;349(2):263-88
pubmed: 8600357
Environ Mol Mutagen. 2011 Dec;52(9):681-4
pubmed: 22167884
Mutagenesis. 1999 Nov;14(6):569-80
pubmed: 10567032
Environ Mol Mutagen. 2018 Jan;59(1):91-95
pubmed: 29076186
Arch Toxicol Suppl. 1995;17:312-25
pubmed: 7786168
Environ Mol Mutagen. 2008 May;49(4):256-64
pubmed: 18288722
IARC Monogr Eval Carcinog Risks Hum. 1990;50:307-83
pubmed: 2152767
Mutat Res. 1979 Jul;61(2):353-79
pubmed: 384224
J Toxicol Sci. 2008 Dec;33(5):515-24
pubmed: 19043273
Environ Mol Mutagen. 2018 Jan;59(1):30-37
pubmed: 28833575
Environ Mol Mutagen. 2008 Oct;49(8):614-21
pubmed: 18626999
Mutat Res. 1996 Jul 5;368(3-4):293-300
pubmed: 8692235
Toxicology. 2008 Jan 20;243(3):261-70
pubmed: 18068886
Environ Mol Mutagen. 2011 Dec;52(9):690-8
pubmed: 21910140
Cell Mol Life Sci. 2001 Dec;58(14):1969-87
pubmed: 11814051
Natl Toxicol Program Tech Rep Ser. 1993 Jan;394:1-274
pubmed: 12637965
J Toxicol Pathol. 2013 Mar;26(1):19-27
pubmed: 23723564
Mutat Res Genet Toxicol Environ Mutagen. 2015 May 1;783:23-35
pubmed: 25953398
Pharm Biol. 2015 Feb;53(2):167-73
pubmed: 25243875
Mutat Res. 1991 Jun;263(2):83-92
pubmed: 1904550
Environ Mol Mutagen. 2010 Oct-Dec;51(8-9):825-35
pubmed: 20857433
Nature. 1995 Oct 19;377(6550):657-9
pubmed: 7566182
J Am Vet Med Assoc. 2001 Mar 1;218(5):669-96
pubmed: 11280396
Environ Mol Mutagen. 2019 Oct;60(8):759-762
pubmed: 31090953

Auteurs

Bas-Jan van der Leede (BJ)

Janssen Research & Development, Beerse, Antwerp, Belgium.

Sandy Weiner (S)

Janssen Research & Development, Spring House, Pennsylvania, USA.

Terry Van Doninck (T)

Janssen Research & Development, Beerse, Antwerp, Belgium.

Kathleen De Vlieger (K)

Janssen Research & Development, Beerse, Antwerp, Belgium.

Ann Schuermans (A)

Janssen Research & Development, Beerse, Antwerp, Belgium.

Fetene Tekle (F)

Janssen Research & Development, Beerse, Antwerp, Belgium.

Helena Geys (H)

Janssen Research & Development, Beerse, Antwerp, Belgium.

Marjolein van Heerden (M)

Janssen Research & Development, Beerse, Antwerp, Belgium.

Sandra De Jonghe (S)

Janssen Research & Development, Beerse, Antwerp, Belgium.

Jacky Van Gompel (J)

Janssen Research & Development, Beerse, Antwerp, Belgium.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH